Remove 2022 Remove Clinical Development Remove Drug Development Remove Licensing
article thumbnail

Successful financing ensures development of Adcendo’s ADC asset 

Drug Discovery World

Michael Pehl, Chief Executive Officer of Adcendo, said: “2022 was a pivotal year for Adcendo with the expansion of our team, uPARAP ADC Development Candidate Nomination and the recent linker/payload license agreement with Duality Biologics.

Licensing 130
article thumbnail

Pfizer launches Phase III trial for Lyme disease vaccine  

Drug Discovery World

VLA15 is the only Lyme disease vaccine candidate currently in clinical development. If the Phase III trial is successful, Pfizer aims to submit a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) and Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) in 2025. .

Vaccine 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Three trends in the antibody-drug conjugate (ADC) market 

Drug Discovery World

The study forecast growth to 2022 and presented an in-depth strategic assessment of the antibody-drug conjugates, highlighting a number of influencing factors impacting or reinforcing market environment, including government policy, technological changes, and market drivers 4.

Marketing 245
article thumbnail

International Women’s Day: Female life science leaders

Drug Discovery World

For International Women’s Day, DDW’s Diana Spencer celebrates some of the women in leadership making an impact on the drug discovery and life sciences sector. She has over 15 years’ experience in corporate finance and restructurings, mergers and acquisitions, joint ventures and intellectual property licensing.

article thumbnail

Taking a new approach to tackle neurodegenerative diseases

Drug Discovery World

million in 2022 to 12.7 The last several years has seen an exponential rise in the understanding of the pathophysiology of AD and in the identification of clinically predictive biomarkers. Diseases such as PSP and FTD have no licensed and available treatments. Volume 23 – Issue 4, Fall 2022. million by 2050.” .

Disease 130
article thumbnail

Europe: Where is the drug discovery innovation?

Drug Discovery World

In 2022, the continent held a 22.4% billion on R&D during 2021, with Germany and Switzerland being the biggest contributors, and around one fourth of clinical trials worldwide were performed in Europe 1. Even before this, however, Amsterdam was established as an important centre for drug development.

Drugs 147
article thumbnail

Why have medicines progressed so little in the last decades?

Drug Discovery World

Dr Pandora Pound , Fellow Oxford Centre for Animal Ethics explores the hinderances of animal testing in pharma and why new technologies such AI, genomics and synthetic biology c an further drug development. Drug discovery and development tomorrow – Changing the mindset. Clinical Development Success Rates 2006-2015.;